CADTH Canadian Drug Expert Committee recommendation. Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity.

CADTH Canadian Drug Expert Committee recommendation. indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity. Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) :

Show other versions (6)

The CADTH Canadian Drug Expert Committee recommends that crelizumab be reimbursed for the management of adult patients with early PPMS as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity, if the following criteria and c...

Full description

Saved in:
Bibliographic Details
Online Access: https://www.ncbi.nlm.nih.gov/books/NBK532699/
Full text
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : CADTH, 2018
Edition:Version: 1.0.
Series:Common drug review clinical review report.
Subjects:
Multiple Sclerosis > drug therapy.
Antibodies, Monoclonal > therapeutic use.
Antibodies, Monoclonal > economics.
Immunologic Factors > economics.
Insurance, Health, Reimbursement > economics.
Insurance, Pharmaceutical Services > economics.
Drug Costs.
Cost-Benefit Analysis.
Canada.

Internet

https://www.ncbi.nlm.nih.gov/books/NBK532699/
Full text

Similar Items